Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0RZ0N
|
||||
| Former ID |
DIB010341
|
||||
| Drug Name |
FR-62765
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] | Terminated | [1] | ||
| Company |
Fujisawa Pharmaceutical Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H18O5
|
||||
| Canonical SMILES |
C1(=C(C(=O)OC1CCC(=O)OCC)OC)c1ccccc1
|
||||
| CAS Number |
CAS 105346-34-7
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Aldose reductase | Target Info | Modulator | [1] | |
| BioCyc Pathway | Methylglyoxal degradation III | ||||
| Acetone degradation I (to methylglyoxal) | |||||
| KEGG Pathway | Pentose and glucuronate interconversions | ||||
| Fructose and mannose metabolism | |||||
| Galactose metabolism | |||||
| Glycerolipid metabolism | |||||
| Metabolic pathways | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| PathWhiz Pathway | Fructose and Mannose Degradation | ||||
| Pyruvate Metabolism | |||||
| Pterine Biosynthesis | |||||
| Glycerolipid Metabolism | |||||
| Galactose Metabolism | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Polyol Pathway | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| References | |||||
| REF 1 | Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats. J Antibiot (Tokyo). 1991 Apr;44(4):441-4. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.